Alexander Wu
Hematology & Oncology · Brewer, MENPI 1285087817
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,206 of the $1,484 with a category attached, or 81.3%. 14 manufacturers reported payments, led by Novartis at 26.0% of the total. Reporting peaked in 2023 at $987 and has fallen 74.9% since, to $248 in 2025.
Across 51 payments — averaging $29.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$386
- Merck$355
- Seagen Inc.$219
- Amgen$124
- Takeda Pharmaceuticals U.S.A., Inc.$89
- Beigene USA, Inc.$77
- plus $234 from 8 others
What the payments were for
- Food & beverage$1,20681%
- Education$27819%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $386 |
| Merck | 16 | $355 |
| Seagen Inc. | 3 | $219 |
| Amgen | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $89 |
| Beigene USA, Inc. | 3 | $77 |
| Pfizer | 2 | $43 |
| Array Biopharma Inc | 2 | $37 |
| Sanofi | 1 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Bayer | 1 | $20 |
| AstraZeneca | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nplate$124
How this compares
$1,484 in reported general payments places this provider in the 60th percentile of 60 hematology & oncology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 17 | $260,616 |
| XtandiEnzalutamide | 13 | $205,488 |
| Lenalidomide | 17 | $200,895 |
| VenclextaVenetoclax | 15 | $186,683 |
| Abiraterone Acetate | 24 | $47,378 |
| Tamoxifen Citrate | 18 | $664 |
| Ondansetron Hcl | 22 | $475 |
| Acyclovir | 23 | $434 |
| Dexamethasone | 56 | $308 |
| Anastrozole | 12 | $267 |
| Hydrocortisone | 11 | $180 |
| Prednisone | 26 | $106 |
| Potassium Chloride | 14 | $59 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Brewer
- Philip BrooksBrewer$6K
- Shruti BhandariBrewer$3K
- Yelena PatsiornikBrewer$1K
- Khalil KamarBrewer$775
- Thomas OpenshawBrewer$488
- Sarah SinclairBrewer$471
- Debasmita SahaBrewer$424
- Erdem AltunelBrewer$373
- Sheila Karina PascualBrewer$265
- Sigrid BergBrewer$221
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.